A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
Recruiting · NCT06972732 · Interventional (participants receive a specific treatment) · Lead sponsor: Boryung Pharmaceutical Co., Ltd
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Has voluntarily agreed to participate in this clinical trial.
- Adults over 19 years of age
- Diagnosed with type 2 diabetes
Exclusion criteria
- Has severe renal and liver disorders
- Has type 1 diabetes
- Those who are participating or have participated in other clinical trials and administered their investigational products within 8 weeks before the screening date for this study
- Those who are deemed ineligible to participate in the study by the investigator
Where it is running
1 location listed.
- The Catholic University of Korea, Seoul St. Mary's Hospital - Seoul, Seocho District, South Korea